Free Trial

Bloom Burton's Rating of AbCellera Biologics on 12/19/2021

On December 19, 2021, Bloom Burton updated its outlook on AbCellera Biologics (NASDAQ:ABCL) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.